Black Diamond Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
BDTX
Black Diamond Therapeutics, Inc. Common Stock
$2.03 +2.53%
VS HALOHalozyme Therapeutics, Inc.
$103.44 -15.88%
Black Diamond Therapeutics, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| BDTX | HALO | |
|---|---|---|
| Market Cap | $113.76 million | $13.96 billion |
| Revenue (TTM) | — | — |
| Net Income (TTM) | $-42,555,000 | — |
HALO leads on 1 of 1 size & scale factors.
Valuation
| BDTX | HALO | |
|---|---|---|
| Price / Book | 1.18 | — |
BDTX and HALO split the valuation factors evenly.
Profitability
| BDTX | HALO | |
|---|---|---|
| Return on Equity | -44.29% | — |
BDTX and HALO split the profitability factors evenly.
Risk & Sentiment
| BDTX | HALO | |
|---|---|---|
| Short Interest | 2.27% | 9.79% |
BDTX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BDTX overview, BDTX financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.